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Abstract  
Early detection of drug-induced cholestasis remains a challenge during drug development. We have 
developed and validated a biorelevant sandwich-cultured hepatocytes- (SCH) based model that can 
identify compounds causing cholestasis by altering bile acid disposition. Human and rat SCH were 
exposed (24-48 h) to known cholestatic and/or hepatotoxic compounds, in presence or in absence of 
a concentrated mixture of bile acids (BAs). Urea assay was used to assess (compromised) 
hepatocyte functionality at the end of the incubations. The cholestatic potential of the compounds 
was expressed by calculating a drug-induced cholestasis index (DICI), reflecting the relative 
residual urea formation by hepatocytes co-incubated with BAs and test compound as compared to 
hepatocytes treated with test compound alone. Compounds with clinical reports of cholestasis, 
including cyclosporin A, troglitazone, chlorpromazine, bosentan, ticlopidine, ritonavir, and 
midecamycin showed enhanced toxicity in the presence of BAs (DICI ≤ 0.8) for at least one of the 
tested concentrations. In contrast, the in vitro toxicity of compounds causing hepatotoxicity by other 
mechanisms (including diclofenac, valproic acid, amiodarone and acetaminophen), remained 
unchanged in the presence of BAs.  A safety margin (SM) for drug-induced cholestasis was 
calculated as the ratio of lowest in vitro concentration for which was DICI ≤ 0.8, to the reported 
mean peak therapeutic plasma concentration. SM values obtained in human SCH correlated well 
with reported % incidence of clinical drug-induced cholestasis, while no correlation was observed 
in rat SCH. This in vitro model enables early identification of drug candidates causing cholestasis 
by disturbed BA handling.  
 
Keywords: drug-induced cholestasis; bile acids; sandwich-cultured hepatocytes; bile salt export 
pump; urea assay; safety margin 
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Abbreviations 
ALT, alanine aminotransferase; ALP, aspartate aminotransferase; BAs, bile acids; 
BSEP/Bsep, bile salt export pump (human/rat); DICI, drug-induced cholestasis index; 
DMSO, dimethyl sulfoxide; TCA, taurocholic acid; CA, cholic acid; FBS, fetal bovine 
serum; GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; HBSS, 
Hanks’ Balanced Salt Solution; NOAEL, no observed adverse effect level; NTCP/Ntcp, 
sodium taurocholate cotransporting polypeptide (human/rat); PBS, phosphate buffered 
saline; SCH, sandwich-cultured hepatocytes; SCRH, sandwich-cultured rat hepatocytes; 
SCHH, sandwich-cultured human hepatocytes; SM, safety margin; ULN, upper limit of 
normal. 
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Introduction 
Cholestasis represents a pathological liver condition characterized by the impairment of bile 
secretion. Cholestasis is associated with accumulation of the bile acids (BAs) and other cholephiles 
in the liver (Fischer et al., 1996). The cytotoxicity of accumulated BAs has been implicated as one 
of the major causes of hepatocellular damage noted during cholestasis (Attili et al., 1986). BAs 
induce apoptosis at lower concentrations (in micromolar range), while they elicit necrotic damage to 
the cells at higher concentrations (in the milimolar range, close to the critical micelle concentration 
of BAs) (Perez and Briz, 2009). 
BAs are synthesized from cholesterol in hepatocytes and their homeostasis is maintained by 
synchronized activity of different enzymes and transport proteins. The synthesized unconjugated 
BAs (e.g. cholic acid, chenodeoxycholic acid) are conjugated with either glycine or taurine and are 
excreted into the bile canaliculi by the bile salt export pump (BSEP/Bsep, ABCB11/Abcb11), an 
ATP-dependent efflux transporter.  Conjugated and unconjugated BAs can further get sulfated or 
glucuronidated in the liver. Sulfated and glucuronidated BAs are transported into the bile canaliculi 
by multidrug resistance associated protein-2 (MRP2/Mrp2, ABCC2/Abcc2). Multidrug resistance 
protein-3 (MDR3/Mdr2, ABCB4/Abcb4) is a floppase that is involved in translocation of 
phosphatidylcholine from the inner to the outer bilayer of the bile canalicular membrane. In the bile 
duct, BAs form mixed micelles after associating with cholesterol and phophatidylcholine. The 
mixed micelles protect the bile duct surface from the detergent effects of the BAs (Elferink and 
Paulusma, 2007). In the intestine secondary BAs (deoxycholic acid, lithocholic acid, and 
ursodeoxycholic acid) are formed by the action of intestinal flora. BAs are taken up by the 
enterocytes via the apical sodium-dependent bile acid transporter (ASBT/Asbt; SLC10A2/Slc10a2 
gene). Heteromeric organic solute transporters OSTα-β, localized in the basolateral membrane of 
the enterocytes, effluxes the BAs to the portal circulation (Rao et al., 2008; Dawson et al., 2009). 
BAs are taken up from the portal blood into the hepatocytes by sodium taurocholate co-transporting 
polypeptide (NTCP/Ntcp; SLC10A1/Slc10a1) and by organic anion transporting polypeptides 
(OATP/Oatp; SLCO/Slco). The hepatic uptake of unconjugated BAs is mainly mediated by 
OATP1B1/Oatp1b2 (SLCO1B1/Slco1b2) while uptake of conjugated BAs is mostly carried out by 
NTCP (Dawson et al., 2009; Xiang et al., 2009; Csanaky et al., 2011). Multidrug resistance 
associated protein-3 and -4 (MRP3/4 and Mrp3/4; ABCC3/4 and Abcc3/4) are the two transporters 
involved in basolateral (= sinusoidal) efflux of BAs. They are upregulated in cholestatic conditions, 
when the canalicular efflux of BAs is compromised (Bohan and Boyer, 2002; Alrefai and Gill, 
2007).  
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Disturbances in the normal physiological function of the transporters and enzymes involved in BA 
homeostasis may lead to cholestasis. Altered enzyme/transporter function may originate from 
genetic mutations in transporters and enzymes and or external factors such as infections, 
inflammation, or physical obstruction of the common bile duct, as in the case of gall bladder stones 
(Epstein et al., 1998; Wagner et al., 2009). Depending on the underlying cause, distinction is made 
between intra- or extra-hepatic cholestasis. Progressive familial intrahepatic cholestasis (PFIC), 
benign recurrent intrahepatic cholestasis (BRIC), vanishing bile duct syndrome are some of the 
forms of intrahepatic cholestasis where modulation of functions of BSEP, MRP2, MDR3 are 
implicated (Pauli-Magnus and Meier, 2006). However cholestasis can occur from changes in a wide 
variety of proteins as listed previously (Balistreri et al., 2005).  
Increased risk of cholestasis has been reported with certain drug therapies (Stieger et al., 2000). 
Drug-induced cholestasis has led to the market-withdrawal of troglitazone and nefazodone, while a 
safety warning has been added to the label of other drugs such as bosentan (Fattinger et al., 2001; 
Funk et al., 2001). Follow-up studies with these compounds have demonstrated (Marion et al., 
2007) inhibition of BSEP by these drugs, leading to intracellular accumulation of BAs and 
subsequent liver toxicity (Stieger et al., 2000; Marion et al., 2007). The putative role of disturbed 
BA homeostasis in different forms of hepatotoxicity has recently been substantiated by an 
untargeted metabolomics study with different hepatotoxicants.  The study of Yamazaki et al., 
(2013) showed that the elevation of BAs in plasma and urine of rats is often one of the early events 
in drug-induced hepatotoxicity (Yamazaki et al., 2013). The relationship between alteration in 
glycine-conjugated BA levels and the in vitro toxicity of exogenously administered primary BAs in 
SCH has been demonstrated as well (Chatterjee et al., 2013).  
Given the multiplicity and complexity of mechanisms underlying drug-induced cholestasis, early 
detection of corresponding safety issues during drug development remains highly challenging. 
Animal models of drug-induced cholestasis can provide valuable mechanistic insights about the 
progression of cholestatic diseases. However, the animal models suffer from several inherent 
differences with the human situation such as: (i) BA pools in humans and rodents are qualitatively 
and quantitatively distinct (Setchell et al., 1997), (ii) the quantitatively major BAs in rodents 
(taurine conjugated) are more hydrophilic and less toxic than the major BAs present in human 
(glycine conjugated) (Rodriguez-Garay, 2003). Not surprisingly, with the current biochemical and 
histological markers only 50 % of the clinical cases of liver toxicity are detected in preclinical 
animal models (Olson et al., 2000). In addition, the in vitro testing models using human hepatocytes 
detected only 50-60 % cases (drugs and drug candidates) of drug-induced liver injury (Xu et al., 
2008).   
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Existing in vitro models for detecting compounds which can cause cholestasis rely on determining 
the extent of inhibition of BSEP-mediated taurocholic acid (TCA) excretion in sandwich-cultured 
hepatocytes (SCH) (B-CLEAR®) (Marion et al., 2007) or in BSEP/Bsep expressing vesicle models 
(Morgan et al., 2010; Dawson et al., 2012). These methods provide unique mechanistic information 
on potential interactions of drug candidate(s) with a representative BA (most often TCA) 
disposition in the liver. However, the limitations associated with these in vitro models are : (i) TCA 
is not a quantitatively important BA in human, and does not seem to play a significant role in 
hepatotoxicity upon its intracellular accumulation (Chatterjee et al., 2013); (ii) the bioanalysis of 
TCA requires the use of a radiolabelled isotope or of LC-MS/MS instrumentation; (iii) multiple 
mechanisms are frequently involved in the toxicity exerted by a compound: even a mild inhibition 
of BSEP/Bsep can potentiate the existing toxicity due to concomitant reactive metabolite formation 
or direct mitochondrial toxicity by the compound (e.g. flutamide, ticlopidine, chlorpromazine) 
(Kang et al., 2008; Anthërieu et al., 2013; Yoshikado et al., 2013); (iv) for some compounds e.g.  
troglitazone, the metabolite (troglitazone sulfate) is a more potent BSEP inhibitor than the parent 
compound (Funk et al., 2001); direct in vitro BSEP inhibition studies with these compounds alone 
may not reveal the full implication of BSEP inhibition in vivo; (v) basolateral efflux of BAs in the 
hepatocytes becomes particularly important during hindrance in their canalicular efflux. For 
instance if a compound also inhibits MRP3/4,(apart from BSEP), BA accumulation at supra-
physiological levels and subsequent bile acid-mediated liver injury is more likely to follow. It is 
noteworthy that inhibition of MRP4 has recently been shown to be associated with toxicity 
associated with certain HIV protease inhibitors (Fukuda et al., 2013).  SCH expressing the 
basolateral and canalicular transporters, provide us with the opportunity to investigate the effect of a 
xenobiotic on the overall disposition of BAs. 
Clearly, evaluation of BSEP/Bsep inhibition is not sufficient to accurately predict drug-induced 
cholestasis for compounds exerting hepatotoxicity via multiple and/or complex mechanisms. This 
illustrates that there is an unmet need for a cost-effective, conceptually simple, higher-throughput in 
vitro model, granting reliable prediction of the liability of new drug candidates regarding drug-
induced cholestasis.  
We have developed a SCH-based in vitro assay to identify compounds that may cause cholestasis 
by interfering with BA disposition. The assay was validated using a set of known cholestatic (as 
positive control) and non-cholestatic but hepatotoxic compounds (as negative control) in both rat 
and human SCH. The clinical relevance of the assay was illustrated by demonstrating a correlation 
between in vitro cholestasis potential and clinical incidence data on cholestasis.  
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Material and Methods  
Materials  
Williams’ E Medium (WEM), L-glutamine, penicillin-streptomycin mixture (contains 10,000 IU/ml 
potassium penicillin and 10,000 µg/ml of streptomycin sulfate), Dulbecco’s modified Eagle’s 
Medium (DMEM), Fetal Bovine Serum (FBS), Hanks’ Balanced Salt Solution (HBSS) (referred to 
as ‘standard buffer’ when pH adjusted to 7.4), Phosphate Buffered Saline (PBS; 1x and 10x), and 
Trypan blue solution (0.4%) were purchased from Lonza Verviers SPRL (Verviers, Belgium). ITS+ 
™ Premix (contains insulin 6.25 mg/l, transferin 6.25 mg/l, selenious acid 6.25 mg/l, bovine serum 
albumin 1.25 g/l and linoleic acid 5.35 mg/l) was purchased from BD Biosciences (Erembodegem, 
Belgium). Sulfuric acid (95-97%) was purchased from Chem-Lab NV (Zedelgem, Belgium). All 
BAs, collagenase type IV (from Clostridium histolyticum), ECM gel (from Engelbreth-Holm-
Swarm murine sarcoma), recombinant human insulin, dexamethasone, urea, diacetyl monoxime, 
thiosemicarbazide, iron (III) chloride hexahydrate, ortho-phosphoric acid, ethylene glycol-bis(2-
aminoethylether)-N,N,N´,N´-tetraacetic acid (EGTA), Dulbecco’s modified Eagle’s Medium 10x 
(DMEM 10x), and 5(6)-carboxy-2´,7´-dichlorofluorescein diacetate (CDFDA) were purchased from 
Sigma-Aldrich (Schnelldorf, Germany). Cyclosporin A, troglitazone, and bosentan were purchased 
from Sequoia Research Products Ltd, UK. HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) was purchased from MP Biochemical (Illkirch, France). 48 and 24-well sterile cell culture 
plates were purchased from Greiner Bio-One BVBA (Wemmel, Belgium). Thermostable 96-well 
plates (for urea assay) were kindly provided by Greiner Bio-One BVBA (Wemmel, Belgium). 
Collagen was prepared in-house from rat tails according to established procedures. Erythromycin 
estolate, midecamycin, and troleandomycin were kindly provided by Prof. Erwin Adams (KU 
Leuven, Pharmaceutical Analysis).  
Animals  
The rats were housed in the Central Animal Facilities of KU Leuven, according to the guidelines 
and policies for animal experiments, housing and care, and the laws of Belgium and European 
Union. Studies were approved by the Institutional Ethical Committee for Animal Experimentation 
of KU Leuven.% Rats were maintained in a 12 h light-dark cycle with free access to water and 
standard rat/mouse maintenance food (ssniff Spezialdiäten GmbH). 
Isolation and culture of rat hepatocytes in sandwich configuration 
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Hepatocytes were isolated from male Wistar rats (170-200 g) based on a two-step collagenase 
perfusion method, as described previously, without adding trypsin inhibitor (Annaert and Brouwer, 
2005). Rats were anaesthetized by an intraperitoneal injection of a mixture of xylazine (24 mg/kg) 
and ketamine (120 mg/kg). After isolation, cells were centrifuged (50 g) for 3 min at 4°C and the 
pellet was re-suspended in WEM containing 5 % FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 
100 µg/ml streptomycin. Hepatocytes were counted using a hemocytometer and cell viability was 
determined using Trypan blue. Cells were re-suspended in WEM containing 5% FBS, 2 mM L-
glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, 4 µg/ml insulin, and 1 µM 
dexamethasone (day-0 medium) and diluted to a final concentration of 1 x 106 cells/ml. Hepatocytes 
used in experiments had viability after isolation of at least 85%. 
Rat hepatocytes were cultured in sandwich-configuration as previously described (Chatterjee et al., 
2013). Briefly, 24-well plates were coated with ice-cold neutralized collagen solution, and placed 
overnight at 37°C in a humidified incubator, and hydrated with PBS before use. Hepatocytes were 
seeded at a density of 0.5 x 106 cells/well, in 500 µl/well of day-0 medium. After incubating the 
cells at 37°C in a humidified atmosphere with 5% CO2 (Binder CO2 incubator, Binder GmbH) for 
1-2 h, unattached cells were removed by shaking the plate and immediately aspirating the medium. 
To obtain a “sandwich” configuration, the cells were overlaid with 50 µl of rat tail collagen solution 
(~1.5 mg/ml, pH 7.4), (day-0). One hour later, pre-warmed day-0 medium was added onto the 
cultures which were kept in a humidified atmosphere with 5% CO2. The medium was changed 
every day with culture medium consisting of WEM containing 1% (v/v) ITS+ ™ Premix, 2 mM L-
glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 0.1 µM dexamethasone (day-1 
medium). 
Sandwich-Cultured Human Hepatocytes 
Human hepatocytes were isolated, cryopreserved and thawed as described previously (Alexandre et 
al., 2012). The demographics and characteristics of the human hepatocyte batches used in the 
present study are listed in Table 1. 48-well sterile cell culture plates were coated one day before 
seeding with 50 µg/ml rigid collagen diluted in 0.02 N acetic acid (250 µl/well), and were placed 
overnight at 37°C in a humidified atmosphere with 5% CO2. Immediately before seeding, the plates 
were washed twice with warm PBS and once with thawing medium. The thawing medium consisted 
of 10% (v/v) FBS, 2 mM L-glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, 4 µg/ml 
insulin, and 1 µM dexamethasone in DMEM, while the seeding medium consisted of WEM, 
supplemented with the same additives as in the thawing medium. After thawing the cells in a 
waterbath (37°C), they were suspended in a mixture of 90 % Percoll® (diluted with with 10x PBS) 
THIS%IS%A%POST)PRINT%VERSION%OF%A%PUBLISHED%MANUSCRIPT.%FINALLY%ACCEPTED%ARTICLE%
AVAILABLE%FROM:%http://www.sciencedirect.com/science/article/pii/S0041008X13004808%
9%
%
and thawing medium (1:1) at 37°C and centrifuged (168 g) for 20 min at room temperature. The 
pelleted cells were re-suspended in thawing medium and centrifuged again for 5 min (100 g) at 
room temperature. The pellet was then re-suspended in seeding medium and hepatocytes were 
counted using a hemocytometer and cell viability was determined using Trypan blue. The minimum 
viability obtained for all the batches was 90%.  Cells were re-suspended in seeding medium and 
diluted to a final concentration of 1 x 106 cells/ml. The seeding density used was 0.2-0.25 x 106 
viable cells/well, depending on the batch of hepatocytes. 24 h after seeding, the hepatocytes were 
overlaid with ECM gel solution (0.25mg/ml) in ice-cold WEM containing 1% (v/v) ITS+ ™ 
Premix, 2 mM L-glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 0.1 µM 
dexamethasone. Medium was changed daily with day-1 medium.  
Determination of urea formation in rat and human SCH 
The capacity of the hepatocytes to convert ammonia to urea was used to assess the overall 
biochemical function and integrity of rat and human SCH. Urea formation by SCRH and SCHH 
was determined following protocols established in our lab (Chatterjee et al., 2013). Briefly, the cells 
were incubated with HBSS containing 10 mM HEPES, 2 mM glutamine, 10 mM ammonium 
chloride and 3 mM ornithine (250 µl/well for 24-well plates; 125 µL/well for 48-well plates) for 1 h 
at 37°C in a humidified atmosphere with 5% CO2. Next, 60 µl of the incubation medium/well was 
mixed with 240 µl of color reagent in a 96-well thermostable plate. The mixture of color reagent 
and incubate was heated at 85°C for 20 min in a water bath and subsequently cooled down by 
keeping the plate at 4°C for 10 min. Absorbance was measured at 525 nm using a Tecan Infinite 
M200 plate reader (Austria).  
Fluorescence Microscopy  
The biliary excretory function in rat and human SCH was assessed by qualitative evaluation of 5(6)-
carboxy-2´,7´-dichlorofluorescein (CDF) excretion in bile canalicular networks via fluorescence 
microscopy (ex/em 490/520 nm), as previously explained (Wolf et al., 2008). Briefly, day-5 SCHH 
and day-3 SCRH were rinsed with standard buffer and then incubated with standard buffer for 10 
min at 37°C. Next, hepatocytes were incubated with 4 µM CDF diacetate (CDFDA) in standard 
buffer. After 10 min incubation at 37°C, the buffer was removed, hepatocytes were washed twice 
with standard buffer before fresh buffer was added. Hepatocytes and bile networks were imaged 
(both by fluorescence and light microscopy) with a VisiCam®3.0 camera (VWR International, 
Leuven, Belgium), mounted on an Olympus IX70 inverted tissue culture microscope (Olympus 
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Optical Co, GMBH, Hamburg, Germany). A monochromator (Polychrome IV; Till Photonics, 
Oberhausen, Germany) was used to generate the excitation wavelength (490 nm). For fluorescence 
microscopy a U-MWIB3 mirror unit was used (emission filter: 510 nm (long pass); dichroic mirror: 
505 nm). 
Incubations with BAs 
Forty to sixty-fold concentrated solutions of a BA mixture (referred to as 40x and 60x BA mixture) 
consisting of the five quantitatively most important BAs present in the human plasma, were used 
(Gnewuch et al., 2009; Scherer et al., 2009; Xiang et al., 2010). The 40x BA mixture consisted of 
52.8 µM glycochenodeoxycholic acid (GCDCA), 15.6 µM of chenodeoxycholic acid (CDCA), 15.2 
µM of glycodeoxycholic acid (GDCA), 16 µM of deoxycholic acid (DCA), and 14 µM of 
glycocholic acid (GCA); the 60x BA mix consisted of 79.2, 23.4, 22.8, 24 and 21 µM of GCDCA, 
CDCA, GDCA, DCA and GCA, respectively. Hepatocytes were first incubated with the test 
compounds alone for 2 h, to provide the test compound time to interfere with bile acid transporters. 
Subsequently, the test compound and the 40-60x BA mixtures (i.e. 60x for experiments with SCRH 
and 40x for experiments with SCHH) were co-incubated for 22 h. After the incubations, urea assay 
was performed for quantitative assessment of (compromised) hepatocytes functionality. For SCHH 
from two donors, hepatocytes were re-exposed a second time for 24 h to compound and BA 
mixture, followed by another urea assay, to assess the effect of re-exposure on in vitro cholestasis 
potency. All the BA solutions were prepared in day-1 medium.  
%
Data Analysis 
The Emax model was used to describe the concentration-dependency of the inhibitory effect of 
troglitazone, bosentan and chlorpromazine (Figure 1) with and without BA mixture, on the capacity 
of hepatocytes to produce urea: 
% % % (Eq.%1)%
Where E is the urea production by hepatocytes, Emax is the urea production under control condition 
(no compound was added), E0 is the urea production at the maximum inhibitory effect of compound 
(and BA mixture), (Emax – E0) is the maximum inhibitory effect. The IC50 is the compound 
concentration (with or without BA mixture) causing 50% inhibition of urea formation. The 
parameter “n” denotes the Hill factor. The best fits of the above equation to the individual urea 
formation data sets were obtained by non-linear regression analysis with the NLS package in R 
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version 2.15.1. The inverse of the experimentally obtained standard deviations were used for 
weighing. 
To quantify the ability of a test compound to exert toxicity by disturbing BA homeostasis in vitro, a 
drug-induced cholestasis index (DICI) was calculated as follows: 
  (Eq. 2) 
DICI values were calculated for each compound at every concentration examined. Compounds were 
classified empirically based on their DICI values: (i) compounds with mild or no potential to cause 
cholestasis: DICI > 0.8; (ii) compounds with moderate cholestasis risk: 0.8 ≥ DICI > 0.5 and (iii) 
compounds with high risk to cause cholestasis: DICI ≤ 0.5.  
Safety margins were calculated for each compound, based on the Cmax (µM, mean peak plasma 
concentration in human, obtained from clinical reports) and the lowest in vitro concentration (µM) 
yielding a DICI < 0.8, as follows: 
  (Eq. 3) 
When DICI was > 0.8 for the highest concentration tested, a minimum safety margin was reported 
(SM > highest concentration/Cmax (µM)). For the test compounds evaluated, the concentration range 
included between the Cmax and Cmax/10 was considered to be the therapeutic plasma 
concentration range (see Figures 2 and 3).  
Statistics 
For troglitazone (Figure 1), the ANOVA (F-test) in MS Excel version 2007 was used to evaluate 
statistical significance of differences between urea formation profiles by SCRH treated with 
troglitazone alone and with troglitazone plus the 60x BA mixture: separately fit profiles for 
troglitazone alone or for troglitazone plus BAs were compared to the simultaneous fit obtained with 
both data sets combined . For each concentration of chlorpromazine and bosentan (Figure 1), a two-
tailed student t-test was used to assess the statistical significance of the differences in urea 
formation (nmol/well) between SCRH treated with compounds alone or SCRH treated with 
compound plus 60x BA mixture. The criterion for statistical significance was p < 0.05. 
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Results!
Influence of BAs on concentration-dependent toxicity of bosentan, troglitazone and 
chlorpromazine in SCRH: proof of concept 
The working hypothesis of the present study was that SCH would be sensitized to the cytotoxic 
effects of BAs upon co-incubation with compounds reported to cause cholestasis in the clinic. To 
test this hypothesis, SCRH were exposed to increasing concentrations of bosentan, chlorpromazine 
and troglitazone with or without a 60x BA mixture. For bosentan concentrations > 100 µM, SCRH 
became sensitive to the toxic effects of BAs. This was reflected by decreased urea formation in 
SCRH co-incubated with bosentan and BA mixture as compared to bosentan or BA mixture alone 
(Figure 1A). 
Similarly, SCRH were also sensitized to the cytotoxic effects of BAs when co-incubating the 
cholestatic compounds chlorpromazine and troglitazone with the 60x BA mixture (Figure 1B-C). In 
case of chlorpromazine, the difference in urea formation between SCRH treated with 
chlorpromazine alone and SCRH co-incubated with chlorpromazine and BA mixture was only 
observed at the highest concentration (30 µM) of chlorpromazine treatment  (Figure 1B). However, 
for troglitazone, co-incubation with the BA mixture resulted in decreased urea formation for all 
concentrations tested (except for 50 µM). The concentration-dependent urea formation profiles for 
troglitazone with and without 60x BA mixture were significantly different from each other (p 
<0.05). 
The effect of BAs in modulating in vitro cytotoxicity of the cholestatic compounds is further 
illustrated in Table 2. The IC50 for reduction of urea formation by the compounds in the presence of 
the BA mixture is consistently lower than when SCRH were treated with compounds alone. The 
concentration-dependent decrease in DICI values (supplementary Table 1) is consistent with the 
cholestatic nature of these compounds. 
Effect of co-incubation with a BA mixture on toxicity of known cholestatic compounds in 
different batches of SCRH 
To determine the effect of the 60x BA mixture on the concentration-dependent toxicity of known 
cholestatic compounds in multiple batches of SCRH, cyclosporin A (n = 6 batches), troglitazone (n 
= 3), bosentan (n = 1), chlorpromazine (n = 2), ritonavir (n = 2) and glyburide (n = 3), were 
incubated with and without BA mixture (Figure 2). Mean (±SEM) DICI values (Eq. 2) were 
determined for each compound following the urea formation measurements in three wells with and 
three wells without BAs. DICI values obtained from incubations with cyclosporin A at ≥ 10 µM and 
for troglitazone at ≥ 75 µM in different batches of SCRH were lower than 0.8. For bosentan, 
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chlorpromazine and glyburide, an increasing number of DICI values were found to be lower than 
0.8, as the concentration of the incubated compounds increased. In contrast, DICI values remained 
> 0.8 for ritonavir at all the concentrations tested (1-200 µM).  
For each compound a safety margin (SM) was obtained (Eq. 3) based on the ratio of lowest in vitro 
concentration for which DICI ≤ 0.8, to the reported plasma Cmax. SM values ranged between 5.6 
for cyclosporin A to 244 for glyburide. For ritonavir a SM > 13.1 was reported since the highest 
evaluated in vitro concentration yielded a DICI > 0.8 (Table 3).  
Effect of co-incubation with a BA mixture on toxicity of known cholestatic compounds in 
different batches of SCHH 
The mean (±SEM) DICI values shown in Figure 3A-B were determined following incubations with 
and without 40x BA mixture in SCHH obtained from various donors (demographics in Table 1) at 
different concentrations of cyclosporin A (n = 6 batches), troglitazone (n = 4), bosentan (n = 4), 
chlorpromazine (n = 2), ritonavir (n = 2), ticlopidine (n = 1), midecamycin (n = 3), rosiglitazone (n 
= 1), erythromycin estolate (n = 1) and troleandomycin (n = 2). Consistent with the results in 
SCRH, experiments with cyclosporin A at ≥ 10 µM and troglitazone ≥ 75 µM produced DICI 
values below 0.8. Incubations with 1 µM of bosentan in one out of four SCHH batches (lot number 
S240908) yielded a DICI lower than 0.8. For chlorpromazine, midecamycin, ticlopidine (100 µM), 
ritonavir, DICI values were observed to go below 0.8 at more than one concentration. However, for 
rosiglitazone, erythromycin estolate and troleandomycin, none of the DICI values were ≤ 0.8. 
Similar to SCRH, a SM value was calculated for compounds in SCHH. SM values varied between 
0.2 in case of bosentan to 15.6 for troglitazone (Table 3). Compounds with SM < 30 are considered 
to show significant risk to cause cholestasis in the clinic (see discussion for details).  
Effect of co-incubation with a BA mixture on toxicity of negative control compounds in 
different batches of SCRH and SCHH 
Compounds that mediate hepatotoxicity by mechanisms other than interfering with BA 
homeostasis, along with a known non-hepatotoxicant (warfarin) were selected as negative control 
compounds. Diclofenac and valproic acid were used as negative control compounds in SCRH 
(Figure 4), yielding DICI values > 0.9 for all the concentrations tested. In SCHH, mean (±SEM) 
DICI values determined for 20 µM amiodarone, 1 mM acetaminophen and 500 µM warfarin were 
always > 0.90 (Table 4). 
Effect of repeated exposure of SCHH to compound and BA mixture on in vitro estimation of 
cholestasis potential 
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The influence of repeated exposure to compounds and the 40x BA mixture on the toxicity of 
bosentan, midecamycin, ritonavir and troleandomycin was evaluated in two batches of SCHH 
(Table 5). Following the urea assay after 24 h incubation, the same cells were re-exposed to the 
same concentration of compound and BA mixture for another 24 h. The DICI values were 
determined both after 24 and 48 h of co-incubation. Consistently lower DICI values were obtained 
after 48 h co-incubation compared to 24 h co-incubation. For ritonavir a DICI ≤ 0.8 was obtained 
after re-exposure (2 incubation periods of 24 h, Table 5), which contrasted to the unchanged DICI 
following single exposure. 
Correlation between safety margin in SCHH and clinical incidences of cholestasis  
To correlate the in vitro estimated cholestasis potential of known cholestatic compounds in the 
current assay (in SCHH) with their clinically-reported incidence data for cholestasis, safety margins 
were calculated (Eq. 3). The incidences of hepatotoxicity were obtained from literature (Ticktin and 
Zimmerman, 1962; Klintmalm et al., 1981; Larrey and Erlinger, 1988; Naschitz et al., 1995; 
Sulkowski, 2004; Humbert et al., 2007; Dhillon and Keating, 2009). As no literature incidence data 
were available for midecamycin, it was not included in this correlation analysis. For troleandomycin 
and ritonavir DICI values obtained after 24 h exposure remained > 0.8 at all concentrations, 
therefore minimum SM values were used for plotting. Two separate correlation analyses were 
carried out (one with and one without bosentan): bosentan yielded a marginally decreased DICI 
value (≤ 0.8, but standard deviation overlapping with 0.8 cut-off) for a low concentration only (no 
concentration-dependent decrease in DICI). Compounds yielding a safety margin > 30 
(rosiglitazone, erythromycin estolate) were not included in the analysis. For cyclosporin A and 
bosentan, the reports from two independent literature sources were combined (weighed to the 
number of patients in the literature reports), while for ritonavir a range was obtained in the literature 
(the mean of the range was used for correlation). No particular clinical marker for cholestasis was 
selected, as the individual reports employed different markers of general hepatotoxicity. Figure 5 
illustrates that clinical incidences of cholestasis decrease with increasing calculated safety margin 
for cyclosporin A, bosentan, troglitazone, ritonavir, chlorpromazine and ticlopidin. A linear 
correlation (r2=0.85; r2 = 0.86, when bosentan included) was obtained between safety margin and 
incidence (%) of cholestasis.  
Discussion    
At the hepatic level, xenobiotics can disturb BA homeostasis, by interfering with any of the 
following stages of BA disposition: (i) uptake of BAs from the basolateral side of the hepatocytes, 
(ii) de-novo synthesis of the BAs (iii) metabolism/conjugation inside the hepatocytes, (iv) efflux of 
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BAs to the bile canaliculi via canalicular transporters, and (v) sinusoidal efflux of BAs via 
basolateral efflux transporters. Consequently, a holistic in vitro model that covers the various stages 
of hepatic BA disposition would be best equipped to accurately predict cholestatic potential of a 
drug (or drug candidate) altering intrahepatic BA homeostasis. Hepatocytes in sandwich-culture 
have been shown to preserve the functions of proteins controlling the different stages of BA 
disposition (Chatterjee et al., 2013; De Bruyn et al., 2013). We have presently developed a SCH 
based assay that can classify drugs/compounds based on their potential to cause cholestasis in the 
clinic via altered BA homeostasis. In vitro biliary excretory capacity of the SCHH used in the 
present study was qualitatively verified at day-5 by measuring MRP2-mediated CDF efflux into bile 
canaliculi (as an in-process control, supplementary Figure 1). 
For the purpose of the present study we have composed a BA mixture, containing five BAs based 
on their quantitative importance in human plasma, as reported previously (Gnewuch et al., 2009; 
Scherer et al., 2009; Xiang et al., 2010). The toxicity exerted by the compounds (alone or in 
combination with the BA mixture) was measured by the urea assay, which is a marker for integrity 
of liver specific-function (Chatterjee et al., 2013). The 40x-60x concentrated BA mixtures selected 
for the present study are higher than the physiological BA levels in plasma, but become relevant in 
case of cholestasis. Hepatic BA concentrations have been reported to reach 430 – 800 µM in case of 
cholestasis (Fischer et al., 1996; Rolo et al., 2003).  
The concentrations of the BA mixtures were selected such that they would not affect the urea 
formation by the cultures when incubated alone. In contrast, co-incubation of the same cultures in 
the presence of the BA mixture and increasing concentrations of a cholestatic compound should 
lead to toxicity (decreased urea formation). In other words, it was hypothesized that the presence of 
BAs in the extracellular medium would sensitize the hepatocytes towards the cholestatic action of 
the compounds interfering with BA homeostasis. An increased toxicity in the presence of the BA 
mixture with 100-200 µM of bosentan, 30 µM of chlorpromazine and with 75-150 µM of 
troglitazone, clearly vindicate this hypothesis (Figure 1). This suggests that at those concentrations, 
the hepatocytes showed decreased ability to dispose off the added BAs, consistent with the 
cholestatic action of the compounds.  
Based on the design of this new in vitro model as well as the results obtained, we introduce the 
concept: “drug-induced cholestasis index” (DICI). DICI is a relative measure for the residual urea 
formation when a cholestatic drug is incubated in the presence of BAs as compared to the urea 
formation when the drug is applied separately. DICI values classify compounds according to their 
ability to potentiate the in vitro cytotoxicity of the BAs in hepatocytes, and this is expected to be 
related to the potential of compounds to cause cholestasis in vivo. The DICI value measurements in 
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human hepatocytes are particularly relevant for clinical conditions, as they may provide indication 
of the cholestatic signature of the compound in the clinic. The interbatch variability of the human 
hepatocytes regarding increasing the toxicity of cholestatic compounds in the presence of BAs 
mixture may reflect to some extent the variability in toxic response of these compounds in the 
clinic. For instance, a DICI of 0.66 ± 0.08  was obtained with 20 µM cyclosporin A in batch 
S0906A, while in S240908 a DICI of 0.21 ± 0.12 was obtained with 15 µM of cyclosporin A 
treatment. A similar interbatch variability was noted for troglitazone, ritonavir, bosentan among 
other compounds. These findings support the use of multiple batches of SCHH to achieve adequate 
sensitivity for detecting cholestatic drug candidates. 
Cyclosporin A and troglitazone are two known cholestatic compounds that elicited a clear 
concentration-dependent decrease of DICI in different batches of SCRH and SCHH (Figure 2 and 
3). In addition, the concentration-dependent decrease of DICI was also observed for bosentan, 
chlorpromazine and troglitazone in rat hepatocytes (Figure 1, Supplementary Table 1). The 
concentration dependency of the DICI values strengthens the hypothesis that disturbances in BA 
homeostasis mediated by the compounds, contributes to the cholestatic effect. 
Rosiglitazone is an analogue of troglitazone with a decreased risk of hepatotoxicity. With 
troglitazone treatment, 1.9 % of the patients had ALT > 3 times upper limit of normal (ULN), as 
opposed to only 0.17 % patients with rosiglitazone (Lebovitz et al., 2002). However, previous 
reports suggested a strong BSEP inhibition potential of rosiglitazone (Dawson et al., 2012). When 
troglitazone and rosiglitazone were evaluated for cholestasis potential with our assay in the same 
batch of human hepatocytes, troglitazone yielded a DICI ~ 0, while the DICI value for rosiglitazone 
was 1.2 at the same concentration (100 µM). The higher DICI for rosiglitazone compared to 
troglitazone illustrates that the assay is competent to differentiate between cholestatic and non-
cholestatic compounds with similar chemical motifs. 
DICI values in the range 1.5-2.0 were obtained for glyburide and ritonavir in SCRH. These 
compounds are reported to interfere with the transporters taking part in BA uptake (Leslie et al., 
2007). At high concentrations, these compounds might prevent the BAs to enter into the 
hepatocytes, thus decreasing the intracellular accumulation and in turn displaying a protective effect 
as illustrated by DICI values exceeding 1. These findings suggest further investigation regarding a 
more sequential incubation design to minimize interference between BAs and cholestatic 
compounds at the hepatic uptake level.  
Further to DICI, corresponding safety margin (SM) values were calculated. The SM reflects the 
ratio of the lowest concentration of the compound that yields a DICI ≤ 0.8 to the mean peak plasma 
concentration that the compound (drug) reaches in the clinic (Cmax). To account for different 
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sensitivity and/or distinct intracellular accumulation and metabolism as applicable in vitro versus in 
vivo, a SM cut-off value of 30 was used to classify compounds as cholestatic versus non-
cholestatic. Thus a compound with a SM < 30 is considered to show significant cholestasis risk in 
the clinic. A SM cut-off value of 30 has been suggested previously for predicting clinical toxicity 
via in vitro models, e.g. for cardiotoxicity (Yao et al., 2008). The rationale for employing this safety 
margin towards compound decisions can be further illustrated by the case of cyclosporin A, which 
has been reported to accumulate in the liver several folds more than in the plasma (Lacerda et al., 
1995). Consistently, when the pharmacokinetic profile of cyclosporin A was simulated in SimCYP 
(Version 12, release 1, Sheffield, UK), the hepatic Cmax was found to be 7.6 times higher than 
plasma Cmax (supplementary Figure 2). While hepatocyte accumulation of cyclosporin A is likely 
to also occur in SCH, the actual accumulation ratio may be different due to distinct transporter and 
metabolizing enzyme expression profiles between in vitro and in vivo. Such in vitro-in vivo 
discrepancies necessitate the use of a safety margin to support reliable compound decisions. In 
addition, recent reports (Dawson et al., 2012; Anthërieu et al., 2013) suggest that hepatotoxicity 
manifested by a compound is contributed by different toxicity-pathways acting simultaneously. 
Again, the safety margin will help to compensate for in vitro-in vivo discrepancies in the 
quantitative role of these pathways.  
For troglitazone, chlorpromazine and ticlopidine, multifaceted events have been reported for their 
toxic outcome. Reactive metabolite formation has been described for troglitazone along with BSEP 
inhibition (He et al., 2004). In addition, the metabolite troglitazone-sulfate has been reported to be a 
much stronger inhibitor of BSEP compared to the parent compound (Funk et al., 2001). The toxicity 
of another drug, chlorpromazine, with 2-5 % incidence of cholestasis (Larrey and Erlinger, 1988; 
Lewis and Zimmerman, 1999; Parmentier et al., 2013), has been attributed to increased oxidative 
stress, inherent mitochondrial toxicity of the compound along with BSEP inhibition and consequent 
BA accumulation (Anthërieu et al., 2013). In contrast, it has not shown strong BSEP inhibition in 
any of the prior in vitro reports (Morgan et al., 2010; Dawson et al., 2012). Oxidative stress in 
addition to the inhibition of other transporters apart from Bsep, such as Mdr3 and Mrp2 have been 
associated with ticlopidine-induced cholestasis (Yoshikado et al., 2013). Previously applied in vitro 
assays using vesicles (Dawson et al., 2012) have shown mild inhibition of hBSEP and rBsep with 
IC50 values of 74 µM and 49 µM, respectively. These concentrations are much higher than the 
clinically relevant free drug concentrations (Dawson et al., 2012). The vesicles/BSEP over-
expressed cell lines lack the metabolic machineries required to produce the clinically relevant 
metabolites exhibiting the oxidative stress. On top of that, they lack the cellular organelles like 
mitochondria, which can be a direct target for many drugs. Therefore, the final clinical toxicity (that 
THIS%IS%A%POST)PRINT%VERSION%OF%A%PUBLISHED%MANUSCRIPT.%FINALLY%ACCEPTED%ARTICLE%
AVAILABLE%FROM:%http://www.sciencedirect.com/science/article/pii/S0041008X13004808%
18%
%
can be contributed by toxic insults arising from multiple pathways, and not only by the direct 
inhibition of BSEP-mediated BA transport by the parent drug) remains poorly detected in current 
drug evaluation programs.  In the presently developed assay clinically relevant SM values of 15.6, 
10.6 and 12.4 were obtained for troglitazone, chlorpromazine and ticlopidine in SCHH, thus 
flagging the three drugs for their cholestasis risk. 
A linear correlation was obtained between reported clinical cholestasis incidences (%) of test 
compounds and their corresponding SM in experiments conducted with human SCH (Figure 5). As 
the SM values of the compounds increase the clinical cholestasis incidence (%) decreases. 
Incidence values based on ALP increase > 2 times upper limit of normal, ULN (with or without 
ALT > 3 times ULN), which has been described as a prominent sign of cholestatic liver injury and 
mixed hepatocellular injury, was preferred whenever available in literature (Navarro and Senior, 
2006; Aithal et al., 2011). The clinical symptomatic difference between cholestasis and other forms 
of hepatotoxicity is not always indicated in literature for the compounds examined here. Therefore 
hepatotoxicity incidence values that were used for bosentan and troglitazone have reported ALT > 3 
time ULN as hepatotoxicity marker (Humbert et al., 2007). Note that midecamycin could not be 
included in the correlation analysis in Figure 5 as clinical cholestasis incidence data could not be 
obtained for it. However, midecamycin has been reported to cause cholestasis, consistent with a SM 
value of 10 in our in vitro assay. This was in contrast with previously reported in vitro BSEP/Bsep 
inhibition potential, yielding a high Ki value (154 µM) (Horikawa et al., 2003).  
Regarding the correlation shown in Figure 5 as well as the more qualitative classification 
represented in Figure 6, the in vitro data were unambiguous for the majority of the test compounds. 
However, further investigation is warranted for bosentan, ritonavir, troleandomycin, and 
erythromycin estolate. The latter represents the only misclassified compound by our in vitro assay. 
In SCHH, the SM for erythromycin was > 69, while the DICI value appeared to increase with 
increasing concentration. This again suggests possible interference between BAs and erythromycin 
at the level of hepatic uptake, as also mentioned above for glyburide and ritonavir in rat 
hepatocytes. Moreover, a higher inhibitory effect on the uptake of BAs has been suggested for 
erythromycin estolate in SCRH, which will further decrease the accumulation and hence the 
expected increased toxicity in presence of BAs may not be evident (Ansede et al., 2010). In 
addition, erythromycin has been shown to accumulate in the liver: 150-fold higher hepatic 
concentrations than serum concentrations have been reported for erythromycin in rats (Lee et al., 
1953). Although the uptake transporters are qualitatively maintained in SCH, a down-regulation of 
uptake transporters with culture time has been reported (Tchaparian et al., 2011). This may decrease 
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the uptake of the drug and hence intracellular accumulation compared to the in vivo situation. 
Investigation with higher concentrations of erythromycin can be suggested to tackle the issue.  
Ritonavir did not yield a DICI ≤ 0.8 after 24 h co-incubation, with the current assay design. This 
resulted in a “minimum” safety margin (> 6.6), meaning that this HIV protease inhibitor could not 
be unambiguously classified as safe (SM cut-off 30) based on the present in vitro data. 
Consequently, the minimum safety margin was used to correlate to incidence (%) of hepatotoxicity 
in Figure 5. The higher hepatotoxicity incidences with ritonavir may be attributed to the fact that the 
patients treated with ritonavir have already become susceptible to liver injury due to the existing 
HIV infection. In addition to that, ritonavir is often co-administered with other anti-HIV drugs such 
as atazanavir which potentiates the cholestasis incidences in the clinic (Rakotondravelo et al., 
2012). The safety margin calculated here is obtained with human hepatocytes that are not infected 
with HIV, neither exposed to other drugs.  A “minimum” safety margin was also employed for the 
antibiotic troleandomycin (SM > 10 in SCHH), which could thus also not be classified as non-
cholestatic. This is consistent with reports of cholestatic jaundice (Ticktin and Zimmerman, 1962) 
warranting further investigation with a higher concentration and possibly different incubation 
design.   
Although bosentan did show a DICI ≤ 0.8 at 1 µM in SCHH (DICI = 0.75 ± 0.14), there was no 
evidence of a concentration-dependent increase in cholestasis potential. In contrast, bosentan did 
show concentration-dependent increase in cholestatic potential in SCRH (Figure 1 and 2). In this 
context, it is noteworthy that bosentan has more potent interaction with rat Ntcp compared to human 
NTCP (Leslie et al., 2007). In addition, following re-exposure of 200 µM bosentan and BA mixture 
to SCHH, the DICI value obtained was ≤ 0.8 (DICI = 0.75 ± 0.16). Taken together this in vitro 
assay classifies bosentan as a compound with a potential cholestasis risk, but requiring further 
investigation (Figure 5 and 6). These findings may explain the differential and complex interplay of 
bosentan with rat and human transporters responsible for BA disposition.  Figure 5 illustrates that 
SM values correlated well with hepatotoxicity incidence percentages, irrespective of whether 
bosentan was included (dotted line) or excluded (solid line).  
Repeated exposure to compounds and BA mixture was examined to improve the sensitivity of the in 
vitro cholestasis model (Table 5). The non-destructive nature of urea assay provided the opportunity 
to re-expose the cells with compound and BA mixture, after one urea assay has been carried out. As 
mentioned above, 100 µM ritonavir produced a DICI ≤ 0.8 after repeated (but not single) exposure. 
Also for cyclosporin A, troglitazone, bosentan, midecamycin and troleandomycin, DICI values 
tended to decrease after repeated exposure.   
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The negative control compounds were selected such that they are known to cause hepatotoxicity 
(diclofenac, valproic acid, amiodarone, acetaminophen), but by mechanisms other than interaction 
with BA homeostasis, along with a non-hepatotoxicant warfarin. None of the negative control 
compounds produced a DICI value ≤ 0.8 in both SCHH and SCRH.  Diclofenac, acetaminophen 
and amiodarone have been reported to cause hepatotoxicity by reactive metabolite formation while 
for valproic acid, the intrinsic toxicity coupled with a reactive acyl glucuronide moiety have been 
implicated in its hepatotoxicity (Bort et al., 1999; Manyike et al., 2000; Kiang et al., 2011; Zahno et 
al., 2011). The test results with negative control compounds suggest that the current assay will not 
result in increased in vitro toxicity of compounds in presence of BA mixture, if the compounds do 
not interfere with BA disposition in vivo. 
Our data warn for ignoring species differences in drug toxicity. The previously reported in vivo 
toxicity of chlorpromazine and troglitazone in rat could not explain the observed clinical toxicity. 
For chlorpromazine, only moderate increase (< 2 times) of aspartate amino transferase (AST) and 
bilirubin levels have been reported in rat (Schoonen et al., 2007). Another study reported no 
significant increase in the levels of bilirubin or ALP, however a three times increase of γ-glutamyl 
transpeptidase was reported (Obata, 1983). In addition, the in vitro BSEP/Bsep inhibition studies 
could not distinguish between the difference in hepatotoxic sensitivity of rat and human towards 
chlorpromazine. Similar hBSEP and rBsep inhibition IC50 values (147µM in human versus 122µM 
in rat) were reported for chlorpromazine (Dawson et al., 2012). However, in the current model a > 3 
times higher SM was obtained for chlorpromazine in rat compared to human, thus corroborating the 
species-specific cholestatic/hepatotoxic response observed. Also the animal models with currently 
available biomarkers could not detect the cholestatic /hepatotoxic nature of troglitazone in rat (Li et 
al., 2002; Marra et al., 2005), although strong Bsep/BSEP inhibition was observed in vitro (Dawson 
et al., 2012). Consistently, the in vitro data presently obtained with our cholestasis assay resulted in 
similar SM values in rat and human SCH (Table 3). Thus, the in vitro cholestasis assay could 
overcome the inability of the present animal models to detect cholestatic nature of drugs; in addition 
it can also indicate the species-specific sensitivity towards cholestatic action of the compounds.  
This model supports the use of sandwich-cultured human (but not rat) hepatocytes as preclinical 
model, as the correlation between SM and incidence is only observed in case of SCHH, but not in 
SCRH. 
In conclusion, we have established a new in vitro model based on sandwich-cultured hepatocytes, to 
assess the potential of a compound to cause cholestasis by disturbing BA homeostasis. The model 
employs toxicity (reduced urea formation capacity) as an endpoint and has been validated with 
positive and negative control compounds in human SCH. With SCHH, 8 out of 9 known cholestatic 
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compounds (with previous reports of disturbing BA homeostasis (Figure 6)) were flagged. 
Ritonavir, bosentan and troleandomycin were identified as compounds with potential cholestasis 
risk requiring further investigation. There were no compounds that were incorrectly flagged for 
cholestasis. We have shown with compounds like chlorpromazine, troglitazone, ticlopidine, that if a 
compound requires metabolism along with BA disposition disturbances to exert its toxicity, the 
model is competent to identify it as a potentially cholestatic compound. This model can give new 
insights into the toxicity mechanisms associated with different hepatotoxicants disturbing BA 
homeostasis. It carries the promise to decrease the use of laboratory animals for preclinical testing 
of drug-induced cholestasis. 
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Figure legends 
Figure 1A-C: Concentration-dependent effect of bosentan (A), chlorpromazine (B) and 
troglitazone (C) on urea formation capacity of day-4 sandwich-cultured rat hepatocytes (SCRH), in 
presence (∆) and absence (○) of a bile acid (BA) mixture. SCRH were pre-incubated for 2 h with 
the test compound followed by 22 h co-incubation with a 60x BA mixture and the test compound. 
Subsequently the urea formation by day-4 SCRH was measured. Each data point represents mean 
(±SEM) urea formation from three wells. The fitted curves were obtained as described in the 
methods section. For bosentan and chlorpromazine alone, toxicity was not observed for a sufficient 
number of concentrations to obtain a fitted curve, therefore no IC50 values were calculated. The 
concentration-dependent urea formation profiles of troglitazone with and without 60x BA mixture 
were significantly different (p < 0.05, denoted by *) from each other. The urea formation with 60x 
BA mixture were significantly different (p < 0.05 denoted by *, student t-test) from the urea 
formation with compounds alone treatment, only at the highest concentrations for bosentan and 
chlorpromazine. 
Figure 2: Drug-induced cholestasis index (DICI) and safety margin (SM) values of different 
concentrations of cyclosporin A, troglitazone, glyburide, ritonavir, chlorpromazine, and bosentan in 
SCRH. Points represent mean (±SEM) DICI values obtained in different batches of SCRH. Unique 
batches of SCRH are designated by the same symbols across different panels. The compounds were 
incubated with and without BA mix (three wells with and three wells without BA mix), as described 
in the methods section, and DICI values were calculated based on the relative urea formation. The 
dotted line on the Y-axis represents a DICI value of 0.8, while the dotted line on the X-axis 
represents the reported Cmax of each compound. The shaded area covers DICI values below 0.8 
(i.e. flagged for cholestasis risk) for concentrations within the therapeutic plasma concentration 
range (between Cmax/10 and Cmax). 
Figure 3A-B: DICI values (at various concentrations) and SM values obtained in SCHH with 
cyclosporin A, troglitazone, bosentan, chlorpromazine, ritonavir, ticlopidine, midecamycin, 
rosiglitazone, erythromycin estolate and troleandomycin. Points represent mean (±SEM) DICI 
values obtained with human hepatocytes from different donors (symbols refer to unique donors 
across different panels; see Table 1 for donor information). DICI values were calculated based on 
the urea assay following 24 h co-incubation of the compounds with or without BA mixture (three 
wells with and three wells without BA mix), as described in the methods section. A DICI value of 
0.8 is indicated by the dotted line on the Y-axis, while the dotted line on the X-axis represents the 
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reported Cmax for each compound. The shaded area covers DICI values below 0.8 (i.e. flagged for 
cholestasis risk) for concentrations within the therapeutic plasma concentration range (between 
Cmax/10 and Cmax). 
Figure 4: Mean (±SEM) DICI (▼) values (at different concentrations) as well as SM values for 
diclofenac and valproic acid in SCRH. The dashed line on the Y-axis represents a DICI value of 
0.8, while a dotted line on the X-axis represents Cmax of the respective compound. The shaded area 
covers DICI values below 0.8 (i.e. flagged for cholestasis risk) for concentrations within the 
therapeutic plasma concentration range (between Cmax/10 and Cmax). 
Figure 5: Correlation between literature reports of incidences of cholestasis (%) and SM values 
(r2=0.85) in SCHH, for cyclosporin A, troglitazone, ritonavir, chlorpromazine, ticlopidine and 
troleandomycin. The dotted line represents the correlation (r2 =0.86) including bosentan (■), which 
yielded borderline DICI values (≤ 0.8) two times in SCHH (see discussion). Incidences were 
obtained from clinical reports of hepatotoxicity of these drugs. The mean incidence from two 
different reports was used for both cyclosporin A and bosentan (weighteded for the number of 
patients). For chlorpromazine and ritonavir the reported range of cholestasis incidence is shown. 
Compounds with a SM > 30 were not included in the analysis (see discussion). Troleandomycin and 
ritonavir (●) did not yield DICI values ≤ 0.8, however the minimum SM values based on the highest 
concentration tested in vitro were below 30. For midecamycin no literature reports of incidence of 
cholestasis (%) were available, hence it was not included in this correlation analysis.  
Figure 6: Classification of compounds based on the in vivo clinical cholestasis report and in vitro 
cholestatic potential with the current assay in SCHH. Compounds that have both reports of clinical 
hepatotoxicity/cholestasis and reports of BAs homeostasis disturbance (in vitro or in vivo) are 
classified in + segments on the Y-axis, while absence of any of these characteristics classifies them 
in – segments on the Y-axis. Compounds that have yielded a SM < 30 are classified in the + 
segment on the X-axis, while compounds with SM > 30 in the – segments on the X-axis. The 
shaded area (top segment) represents compounds that have reports of both clinical 
hepatotoxicity/cholestasis and BAs homeostasis disturbance, but could not be classified as safe with 
a SM > 30 (their minimal SM fell below 30 based on DICI at highest concentration tested). 
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Table 1: The demographics and batch characteristics of the cryopreserved human hepatocyte 
batches (donors) used in this study. * indicates that batch SC1034 was a freshly plated human 
hepatocyte batch. Bile canaliculi formation was evaluated (see supplementary Figure 1) based 
on CDF excretion capacity of the SCHH, with fluorescence microscopy. The symbols for the 
human hepatocytes batches used in Figure 3A and 3B are also represented. 
Lot number 
(symbol) 
Gender Race Age 
(years) 
Viability 
(%) 
Yield 
(million/vial) 
Bile 
canaliculi 
function 
B0403VT  (Ο) 
 
Female Caucasian 47 90 9 Yes 
SC1034* () Male Caucasian 58 78 (NA) Yes 
S240908 () Female Caucasian 49 93 9 Yes 
S0312VT (Φ) Male Caucasian 58 92 11 Yes 
S0906A (Π) Female Caucasian 72 92 7.5 Yes 
S1108VT (
) Female Caucasian 41 90 9 Yes 
S1409A (Ø) Female Caucasian 75 90 8 Yes 
S0212A () Male Caucasian 61 92 5 Yes 
S2203LT (	) (NA) (NA) (NA) 92 12 Yes 
NA = Not available 
Table 2: IC50 ± SD (µM) for bosentan, chlorpromazine and troglitazone with and without 60x 
BA mixture in SCRH. The IC50 values were obtained as described in the methods section. For 
bosentan and chlorpromazine incubated alone, toxicity was not observed for a sufficient 
number of concentrations to obtain a fitted curve. Therefore no IC50 values were calculated, 
instead the minimum IC50 (µM) values (from highest concentration tested) are reported.  
 With 60x BA Compound alone 
Bosentan 135 ± 5.5        >  200 
Chlorpromazine 25.0 ± 1.8 >  30 
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Troglitazone 92.3 ± 3.8 126 ± 0.2 
Table 3: Safety margins (SM) for different model drugs evaluated in both SCHH and SCRH 
evaluated in the present study. The safety margins were calculated as described in the 
methods section. 
 
Compound name SCRH SCHH 
Bosentan 13.5 0.14 
Ritonavir > 13.1 > 6.60 
Cyclosporin A 5.60 8.30 
Midecamycin (ND) 10.2 
Troleandomycin (ND) > 10.2 
Chlorpromazine 31.9 10.6 
Ticlopidine (ND) 12.4 
Troglitazone 11.7 15.6 
Erythromycin estolate (ND) > 68.7 
Rosiglitazone (ND) > 96.2 
Glyburide 244 (ND) 
 
ND= Not determined 
 
Table 4: Mean (± SEM) DICI values of amiodarone, acetaminophen and warfarin in SCHH. 
 
Compound Concentration (µM) Lot number DICI SEM 
Acetaminophen 1000 S1108VT 0.93 
Amiodarone 20 SC1034 1.24 
Warfarin 500 S0212A 1.31 
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Table 5: Effect of repeated exposure of SCHH to compound and BA mixture on drug-induced 
cholestasis index (DICI) values (mean ± SD). Cyclosporin A and troglitazone were evaluated 
in the same batch batch, while other compounds in a different batch. The values in bold show 
DICI ≤ 0.80. 
 
 24 h co-incubation 48 h co-incubation 
Bosentan 1 µM 1.11 ± 0.09 1.02 ± 0.13 
Bosentan 5 µM 0.98 ± 0.03 0.85 ± 0.07 
Bosentan 10 µM 1.03 ± 0.09 0.98 ± 0.11 
Bosentan 200 µM 0.85 ± 0.07 0.75 ± 0.16 
Cyclosporin A 15 µM 0.74 ± 0.15 0.46 ± 0.18 
Midecamycin 100 µM 1.00 ± 0.19 1.07 ± 0.07 
Ritonavir 1 µM 0.95 ± 0.09 0.92 ± 0.12 
Ritonavir 50 µM 1.02 ± 0.12 0.92 ± 0.08 
Ritonavir 100 µM 0.99 ± 0.08 0.80 ± 0.39 
Troglitazone 100 µM 0.66 ± 0.13 0.61 ± 0.09 
Troleandomycin 10 µM 1.00 ± 0.09 0.83 ± 0.26 
Troleandomycin 20 µM 1.12 ± 0.13 0.91 ± 0.08 
 
Table 6: Incidence (%) of hepatotoxicity, clinical hepatotoxicity marker, number of patients 
used in the respective study and reported human BSEP inhibition IC50 (µM) for the model 
cholestatic drugs used in our study. 
 
Drug  hBSEP 
inhibition 
IC50 (µM) 
Incidence 
(%) 
Clinical 
markers 
Patient 
population 
Reference 
Bosentan 38.1 7.2  ALTd > 3 
ULNb 
4623 pulmonary 
arterial 
hypertension 
patients 
(Dawson et 
al. 2012; 
Humbert et 
al. 2007) 
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  11 ALT > 3 
ULN 
658 pulmonary 
arterial 
hypertension 
patients 
(Dhillon and 
Keating 
2009) 
Chlorpromazine 147.6  2-5  ALT > 3 
ULN 
 (Dawson et 
al. 2012; 
Larrey and 
Erlinger 
1988) 
Cyclosporin A 0.5 19.7 Bilirubin>2 
ULN 
66 renal 
transplant 
patients 
(Dawson et 
al. 2012; 
Klintmalm et 
al. 1981) 
  4.4 Elevation of 
liver enzymes 
and bilirubin 
705 kidney 
transplant, 112 
heart transplant, 
75 liver 
transplant  
Web 
reference 1 
Erythromycin 
estolate 
4.1 2 ALPe > 3 
ULN 
 (Dawson et 
al. 2012; 
Lewis and 
Zimmerman 
1999) 
 
Ritonavir 
 
2.2 
 
5.3-9.5 
 
ALT, AST > 
3 ULN 
 
1270 infected 
patients 
 
(Morgan et 
al. 2010; 
Sulkowski 
2004) 
Rosiglitazone 6.4 0.17 ALT> 3 
ULLR  
3503 diabetic 
patients 
(Dawson et 
al. 2012; 
Lebovitz et 
al. 2002) 
Ticlopidine 74 4 ALP > 3 
ULN 
 (Dawson et 
al. 2012); 
Web 
reference 2 
Troglitazone 2.7 1.9 ALT> 3 
ULLRc  
2510 diabetic  
patients 
(Dawson et 
al. 2012; 
Lebovitz et 
al. 2002) 
Troleandomycin (ND) 4 ALP >3 ULN 50 (Ticktin and 
Zimmerman 
1962) 
 
bUpper limit of normal; cUpper limit of reference range; dAlanine aminotransferase; eAlkaline 
phosphatase 
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